Sinus Node and Atrial Arrhythmias

Circulation. 2016 May 10;133(19):1892-900. doi: 10.1161/CIRCULATIONAHA.116.018011.

Abstract

Although sinus node dysfunction (SND) and atrial arrhythmias frequently coexist and interact, the putative mechanism linking the 2 remain unclear. Although SND is accompanied by atrial myocardial structural changes in the right atrium, atrial fibrillation (AF) is a disease of variable interactions between left atrial triggers and substrate most commonly of left atrial origin. Significant advances have been made in our understanding of the genetic and pathophysiologic mechanism underlying the development and progression of SND and AF. Although some patients manifest SND as a result of electric remodeling induced by periods of AF, others develop progressive atrial structural remodeling that gives rise to both conditions together. The treatment strategy will thus vary according to the predominant disease phenotype. Although catheter ablation will benefit patients with predominantly AF and secondary SND, cardiac pacing may be the mainstay of therapy for patients with predominant fibrotic atrial cardiomyopathy. This contemporary review summarizes current knowledge on sinus node pathophysiology with the broader goal of yielding insights into the complex relationship between sinus node disease and atrial arrhythmias.

Keywords: ablation, catheter; atrial fibrillation; atrial standstill; pacemaker, artificial; sick sinus syndrome; sinoatrial node.

Publication types

  • Review

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use
  • Animals
  • Atrial Fibrillation / diagnosis*
  • Atrial Fibrillation / epidemiology
  • Atrial Fibrillation / therapy*
  • Brugada Syndrome / diagnosis
  • Brugada Syndrome / epidemiology
  • Brugada Syndrome / therapy
  • Cardiac Conduction System Disease
  • Cardiac Pacing, Artificial / methods
  • Humans
  • Sick Sinus Syndrome / diagnosis*
  • Sick Sinus Syndrome / epidemiology
  • Sick Sinus Syndrome / therapy*
  • Sinoatrial Node / pathology

Substances

  • Adrenergic beta-Antagonists